Clin2
NCT07236203Possibly a fitRecruiting

Study of CAR-T therapy for relapsed large B-cell lymphoma

Large B-Cell Lymphoma

Treatments studied

Part of Blood & lymphatic, Cancer clinical trials.

This study looks at factors that predict how well CAR-T therapy works for large B-cell lymphoma that has come back or not responded to treatment. It aims to help doctors better identify who may benefit from this therapy.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
80 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You have been diagnosed with large B-cell lymphoma (a type of blood cancer that affects certain immune cells).
  • Your lymphoma has returned or not responded after at least two rounds of standard treatment.
  • You plan to receive a CAR-T therapy that is approved by the Chinese drug authority (NMPA).
  • You are willing to sign a consent form to participate.
  • You are not pregnant or breastfeeding.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06479356Recruiting· Phase 2
CAR T-cell therapy for relapsed large B-cell lymphoma

This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.

Tianjin, Tianjin Municipality
NCT04889716Recruiting· Phase 2
CAR-T followed by antibody treatment for lymphoma

This Phase 2 study looks at giving CAR-T cell therapy first, then follow-up “bispecific” antibody medicines to help keep large B-cell lymphoma from coming back. It’s for people whose lymphoma returned or did not respond to prior standard treatments and who still have measurable disease on scans.

Omaha, Nebraska
NCT05826535Recruiting· Phase 1/Phase 2
Test of CAR T-cell therapy for aggressive B-cell lymphoma

This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.

Irvine, California
NCT06760156Recruiting· Phase 2
Tafasitamab and Lenalidomide after CAR-T for Large B-cell Lymphoma

This trial tests a combination of two drugs, tafasitamab and lenalidomide, as a first follow-up treatment for people with large B-cell lymphoma that did not fully go away after CAR-T therapy. The goal is to see if this drug pair can help shrink or control the remaining cancer.

Tampa, Florida
NCT07788118Recruiting· Phase 1/Phase 2
A new car-t therapy for relapsed large b-cell lymphoma

This trial tests a new type of CAR-T cell therapy that may be better at remembering and attacking lymphoma cells. It is for people with large B-cell lymphoma that has not responded to standard treatments or has come back.

Hangzhou, Zhejiang
NCT07524816Recruiting
CAR-T Cell Therapy for Relapsed Lymphoma

This trial tests an experimental CAR-T cell therapy—a treatment that uses your own immune cells modified to fight cancer—for B-cell lymphoma that has returned or stopped responding to previous treatments. Researchers are studying how well this therapy works in real-world practice.

Lyasny, Minsk Oblast

Hear when a new Large B-cell Lymphoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.